40
Participants
Start Date
October 6, 2023
Primary Completion Date
April 30, 2024
Study Completion Date
May 30, 2024
MDI-1228_mesylate Ophthalmic Solution
"MDI-1228\_mesylate Ophthalmic Solution includes 2 strengths:~* 0.1% (0.4 mL \[0.4 mg\] free base)~* 0.3% (0.4 mL \[1.2 mg\] free base)"
Placebo
The components employed in the placebo formulation are the same as those used for the active formulation except MDI-1228\_mesylate is absent.
CMAX Clinical Research, Adelaide
Shanghai Medinno Pharmaceutical Technology Co., Ltd.
INDUSTRY